<DOC>
	<DOCNO>NCT00390520</DOCNO>
	<brief_summary>This mechanistic study design investigate effect vildagliptin sensitivity a-cell glucose hypoglycemic condition patient type 2 diabetes ( T2DM ) .</brief_summary>
	<brief_title>Efficacy Safety Vildagliptin Versus Placebo Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Patients T2DM , diagnose least 6 week prior visit 1 , treatment oral antidiabetic agent least 12 week prior study entry ( visit 1 ) treatment oral antidiabetic agent time past &gt; 3 consecutive month &gt; /= 18 year Body mass index range 2235 kg/m2 HbA1c &lt; /=7.5 % Type 1 diabetes Acute metabolic diabetic complication Evidence significant diabetic complication Insulin treatment within past 6 month Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>glucagon</keyword>
	<keyword>hypoglycemia</keyword>
</DOC>